Research from Mayo Clinic Florida Has Provided New Data on Lentivirus (Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma).

Researchers at Mayo Clinic Florida have conducted a study on repurposing the biomarker c-erb-B2, typically associated with breast cancer, for use in melanoma treatment. By constructing a lentivirus encoding c-erb-B2, they were able to achieve anti-tumor responses in preclinical mouse models and demonstrated successful long-term survival rates. This novel strategy shows promise in the context of emerging anti-HER2/neu antibody-drug therapies, highlighting its potential significance in melanoma treatment. The study was published in Scientific Reports and can be accessed for free online. [Extracted from the article]

Copyright of Cancer Gene Therapy Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)